Overview
Stealth Peptides was founded in 2006 with technologies licensed from several academic institutions. Stealth Peptides has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500-700 Daltons each) that target mitochondria. Published data for these compounds suggest significant in vitro and in vivo efficacy for cardiovascular, renal, neurologic and metabolic diseases.The intellectual property portfolio around these compounds is incredibly robust with compositions including Bendavia™ protectable by patent until 2031.